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Abstract 
Background: One of the major challenges for control and elimination of malaria is ongoing spread and emergence 
of drug resistance. While epidemiology and surveillance of the drug resistance in falciparum malaria is being explored 
globally, there are few studies on drug resistance vivax malaria.
Methods: To assess the spread of drug‑resistant vivax malaria in Myanmar, a multisite, prospective, longitudinal study 
with retrospective analysis of previous therapeutic efficacy studies, was conducted. A total of 906 from nine study 
sites were included in retrospective analysis and 208 from three study sites in prospective study. Uncomplicated vivax 
mono‑infected patients were recruited and monitored with longitudinal follow‑up until day 28 after treatment with 
chloroquine. Amplification and sequence analysis of molecular markers, such as mutations in pvcrt‑O, pvmdr1, pvdhps 
and pvdhfr, were done in day‑0 samples in prospective study.
Results: Clinical failure cases were found only in Kawthaung, southern Myanmar and western Myanmar sites within 
2009–2016. Chloroquine resistance markers, pvcrt‑O ‘AAG’ insertion and pvmdr1 mutation (Y976F) showed higher 
mutant rate in southern and central Myanmar than western site: 66.7, 72.7 vs 48.3% and 26.7, 17.0 vs 1.7%, respec‑
tively. A similar pattern of significantly higher mutant rate of antifolate resistance markers, pvdhps (S382A, K512M, 
A553G) and pvdhfr (F57L/I, S58R, T61M, S117T/N) were noted.
Conclusions: Although clinical failure rate was low, widespread distribution of chloroquine and antifolate resistance 
molecular makers alert to the emergence and spread of drug resistance vivax malaria in Myanmar. Proper strategy and 
action plan to eliminate and contain the resistant strain strengthened together with clinical and molecular surveil‑
lance on drug resistance vivax is recommended.
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Background
Plasmodium vivax is the most globally widespread 
malaria parasite, causing significant high public health 
issues in many countries. World Health Organiza-
tion (WHO) estimated 13.8 million vivax cases glob-
ally in 2015. Although vivax was believed to be a benign 
infection, death related to severe vivax malaria was esti-
mated around 1400–14900 cases in 2015 globally [1].
A decreasing trend in malaria promises the possibil-
ity of malaria elimination and many endemic countries 
are moving forward to malaria elimination [1]. One of 
the major challenges to achieve the elimination goal is 
drug-resistant falciparum and vivax infection. Unlike fal-
ciparum, drug-resistant vivax is difficult to detect, con-
firm and monitor because of the nature of vivax malaria, 
such as the presence of hypnotize stage, low level para-
sitaemia, asymptomatic carriers, and lack of long-term 
in vitro testing [2, 3].
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In the era of pre-elimination, relatively increased 
prevalence on vivax was observed [1]. In Myanmar, 
vivax malaria was the second most common malaria 
species composed of approximately 30 percent of all 
malaria cases until 2014 [1]. Afterward, the relative 
prevalence of the vivax has been increasing. Chloro-
quine (Chloroquine Phosphate Tablet BP, Remedica Ltd-
Cyprus) 25  mg/kg for 3  days followed by primaquine 
(Remedica Ltd-Cyprus) 0.25  mg/kg for 14  days is the 
recommended treatment for vivax malaria in Myanmar 
while ACT (artemisinin-based combinational therapy) 
has been using to treat falciparum malaria since 2003. 
Although artemisinin resistance falciparum malaria was 
confirmed by clinically and molecular approaches, very 
few document on drug resistance vivax malaria was 
reported in Myanmar.
Chloroquine-resistant vivax malaria was first reported 
in Papua New Guinea in 1989 [2]. Chloroquine-resist-
ant vivax has been confirmed in ten countries, includ-
ing Myanmar [1], and treatment failure within day 28 or 
chemoprophylaxis failure with chloroquine was reported 
in 21 countries [3]. Unfortunately, there are no accepted 
and validated molecular markers for chloroquine or other 
anti-malarial for resistant vivax malaria. However, poten-
tial molecular makers for chloroquine-resistant vivax, 
such as mutations in pvcrt-O (P. vivax chloroquine resist-
ance transporter-O) and pvmdr1 (P. vivax multidrug 
resistance protein 1) and antifolate resistant vivax such as 
pvdhps (P. vivax dihydropteroate synthetase) and pvdhfr 
(P. vivax dihydrofolate reductase) were used for molecu-
lar detection to estimate the underlying drug resistance. 
As there is no documented study on molecular markers 
analysis on vivax malaria, clinical and molecular mark-




The study included the retrospective analysis of previ-
ously conducted therapeutic efficacy studies (TES) of 
chloroquine in uncomplicated vivax malaria in Myanmar 
and prospective multi-site, longitudinal study by clinical 
and molecular markers analysis. From 2009 to 2012, TES 
on vivax malaria was conducted in nine sentinel sites 
(Fig. 1) which covered most of the malaria-endemic areas 
in Myanmar. In 2012, Shwegyin, in the southern part of 
central Myanmar, was selected for TES of chloroquine 
as this study site has a high burden of both falciparum 
and vivax malaria among migrant goldmine workers. In 
2015–2016, TES of chloroquine on vivax malaria was 
conducted in Buthidaung, in the western border area and 
Kawthaung, southern Myanmar.
Procedure
All procedures on case selection, recruitment and follow-
up were carried out according to the standardized pro-
tocol recommended by WHO [4]. Briefly, uncomplicated 
vivax mono-infected patients over 6 years old with fever 
or history of fever within previous 48  h, were recruited 
and treated with chloroquine standard dose calculated 
by body weight, followed by observation with follow-up 
schedule, i.e., day 3, 7, 21 and 28 after treatment. Clinical 
and parasitological assessment was done on each follow-
up day. All anti-malarials used in this study were pro-
vided by the national malaria control programme.
Blood samples were taken on day 0 and all follow-up 
days for microscopic examination and molecular analy-
sis. Blood film examination on peripheral blood smear 
was carried out after 3% Giemsa stain for 45 min. Blood 
film examination was done as described [4] and calcu-
lated as parasite count per µL of blood. For molecular 
analysis, finger-prick blood samples were collected on fil-
ter paper (Whatman©), dried and stored in plastic bags 
with desiccant until analysis. Molecular markers analy-
sis was conducted only in prospective study sites such as 
Kawthaung, Shwegyin and Buthidaung.
Molecular analysis
All day-0 samples were subjected to analysis for distri-
bution and spread of chloroquine and antifolate drug 
resistance markers. Filter papers were prepared and 
extracted for parasite genomic DNA using QIAamp DNA 
Blood Mini Kit (QIAGEN) according to manufacturer’s 
instruction. The target genes were amplified by using the 
specific pair of primers (Table  1). In this study, chloro-
quine resistance marker, ‘AAG’ insert in pvcrt-O; multi-
drug resistance marker, mutations in pvmdr1; antifolate 
resistance makers, mutations in pvdhps and pvdhfr were 
amplified and analysed.
PCR reactions were performed in a reaction mixture 
that contained 0.25 mM of each dNTP, 10 mM Tris–HCl 
(pH 9.0), 30  mM KCl, 1.5  mM MgCl2, 1.0 units of Taq 
polymerase (Accupower© premix, Bioneer, Seoul, Korea), 
0.02 µM primers, and 2 µL of genomic DNA.
For target gene amplifications, initial denaturation at 
95  °C for 10 min was followed by 35 cycles of 95  °C for 
30 s, 58 °C (pvdhps) or 60 °C (pvcrt-O) or 62 °C (pvdhps 
and pvdhfr) for 45 s, 72 °C for 1 min, and a final extension 
of 72  °C for 10  min. Amplified products were checked 
by 1% agarose gel electrophoresis stained with Red safe© 
(iNtRON, Seongnam, Republic of Korea). The PCR 
clean-up was proceeded by MEGAquick-spin DNA frag-
ment purification Kit  (iNtRON, Republic of Korea) and 
sequencing. The nucleotide and amino acid sequences 
were aligned and analysed by Lasergene® software 
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(DNASTAR, Madison, WI, USA) using the reference 
strain of Sal-1 retrieved from Plasmodium data base [5]. 
The nucleotide sequences were submitted to GenBank 
under accession numbers KX000945–KX000959.
Statistical analysis
For clinical data, efficacy outcomes were classified as 
adequate clinical and parasitological response (ACPR) 
for successful cure cases until day 28 after treatment or 
treatment failure (TF) that may be early treatment fail-
ure (ETF): failure until day 3 after treatment; or late treat-
ment failure (LTF): failure within days 3 to 28. Data were 
counter-checked and analysed by MS Excel and SPSS 
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Fig. 1 Retrospective and prospective analysis of the clinical surveillance of drug resistance in vivax malaria in Myanmar (2009–2016). Retrospective 
analysis was conducted in 906 vivax infected cases in nine sentinel sites. Prospective study with molecular surveillance was conducted in Buthi‑
daung (western Myanmar in 2015), Shwegyin (central Myanmar in 2014) and Kawthaung (southern Myanmar in 2015–2016). Clinical failure cases 
were found only at southern and western Myanmar
Table 1 Pairs of primers used to amplify the target genes
Target gene Primer name Primer sequences (5’→3’)
pvcrt‑O Pvcrto_F TCC TTG CCG CTG ATT CTA CG
Pvcrto_R GGT AAC GTT CAT CGG GGG TT
pvmdr1 Pvmdr1_F3 GGA TAG TCA TGC CCC AGG ATT G
Pvmdr1_R3 CAT CAA CTT CCC GGC GTA GC
pvdhfr Pvdhfr_F1 ATG GAG GAC CTT TCA GAT GTA TT
Pvdhfr_R1 CCA CCT TGC TGT AAA CCA AAA AGT 
CCA GAG
pvdhps Pvdhps_D GGT TTA TTT GTC GAT CCT GTG
Pvdhps_B GAG ATT ACC CTA AGG TTG ATG TAT C
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(Version 22.0. IBM Corp., Armonk, NY, USA). Pear-
son’s Chi squared test or Fisher’s exact test was used to 
determine with a P value of <0.05 accepted significant. 
Mann–Whitney test was calculated for non-parametric 
analysis on non-normal distribution. Individual as well as 
co-occurrence of mutations were analysed and compared 
among different sentinel sites.
Ethical consideration
Participation in this study was entirely voluntary. Writ-
ten consent was taken from all participants. This project 
obtained ethical clearance from the ethical committee 
of the Department of Medical Research, Republic of the 
Union of Myanmar (Approval No-52/Ethics, 2012 and 
31/Ethics, 2015) and institutional ethical committee of 




During 2009–2012, TES of chloroquine on 906 uncom-
plicated vivax malaria infected cases was conducted 
in nine sentinel sites in Myanmar (Fig.  1). LTF cases, 
according to the WHO definition [4], were reported in 
Kawthaung (southern Myanmar), Sagaing and Buthi-
daung (western Myanmar) sites only while there was no 
treatment failure cases until day 28 follow-up in remain-
ing study sites. The highest failure rate was noted in Kaw-
thaung in 2012 (18/60, 30%). Kawthaung and Buthidaung 
site showed failure cases in every study period. There was 
no early treatment failure case in all study sites.
Prospective longitudinal study
Kawthaung (southern Myanmar), Shwegyin (central 
Myanmar) and Buthidaung (western Myanmar) were 
selected for prospective longitudinal study after treat-
ment with chloroquine regimens. A total of 208 uncom-
plicated vivax cases were included in this study with 
mean age of 24.2 (±9.03) years and geometric mean of 
the parasite density of 4160 with 95% CI (3567–4851) 
(Table 2). There was no clinical failure case in Shwegyin, 
but one LTF case in Kawthaung at day 28 (1/60, 1.7%) 
and two in Buthidaung at days 21 and 28 (2/60, 3.3%).
Molecular marker analysis
All day-0 samples collected from three sentinel sites were 
analysed for molecular markers (Fig.  2; Table  3). More 
than half of the samples (133/204, 63.9%) showed K10 
‘AAG’ insertion in chloroquine resistance transporter 
gene, pvcrt-O. Among them, Shwegyin showed the high-
est mutant rate (64/88, 72.7%) followed by Kawthaung 
(40/60, 66.7%) and Buthidaung (29/60, 48.3%). Similarly, 
pvmdr1 (Y976F) was found in Kawthaung, Shwegyin and 
Buthidaung as 16/60, 26.7%; 15/88, 17.0% and 1/60, 1.7%, 
respectively. Interestingly, significant highest mutant 
rate of F1076L was observed in Buthidaung (38/60, 
63.3%) (p  =  0.067). To estimate the chloroquine resist-
ance status, pvcrt-O (K10 insertion) and pvmdr1 muta-
tions (Y976F and F1076L) were analysed together. Only 
K10 insertion was lowest in Buthidaung (29/60, 48.3%) 
with highest rate of F1076L alone or with K10 insertion 
together. However, the number of isolates showing K10 
insert in pvcrt-O gene as well as both pvmdr1 mutations 
(Y976F and F1076L) was highest in Kawthaung (11/60, 
16.7%) followed by Shwegyin (11/88, 12.5%) and no iso-
late in Buthidaung (Tables 3, 4). Similarly, all mutations 
of pvdhps (S382A, A383G, K512M, A553G) showed the 
highest in Kawthaung (17/60, 28.3%) followed by Shw-
egyin (6/88, 6.8%) and Buthidaung (2/60, 3.3%) (Table 3). 
Moreover, half of the samples showed the wild type 
pvdhps alleles while no wild type in Kawthaung and one 
only (1/88, 1.1%) in Shwegyin (Table 4).
Furthermore, mutations in pvdhfr gene were analysed 
and all mutations, F57L/I, S58R, T61M, and S117T/N, 
showed the highest mutant rate in Shwegyin (70/88, 
79.5%) followed by Kawthaung (45/60, 75.0%). Wild type 
alleles were found only in Buthidaung (5/60, 8.3%). Triple 
or quadruple mutant alleles of pvdhps was observed and 
accounted for more than 50% of samples in all study sites 
(Table  4). A combined analysis of all mutations in 208 
samples totaled 80 different genotypes (Additional file 1).
Discussion
This study explores the clinical and molecular pattern 
of candidate drug resistance markers in Myanmar. Ret-
rospective and prospective analysis on TES of chlo-
roquine on vivax malaria (2009–2016) showed that 
Table 2 Basic characteristics of the study participants
SD standard deviation, M male, F female, CI Confident interval, ACPR adequate clinical and parasitological response
Characteristics All site (n = 208) Kawthaung (n = 60) Shwegyin (n = 88) Buthidaung (n = 60) P value
Mean age (SD) 24.16 (9.03) 26.27 (10.72) 22.59 (7.99) 24.35 (8.30) 0.091
M:F 1.6:1:0 9.0:1.0 4.5:1.0 60.0:0.0 0.002
Parasite count (p/μL) geometric mean (95% CI) 4160 (3567–4851) 3325 (2404–4597) 4795 (3866–5948) 4225 (3140–5685) 0.520
ACPR (n, %) 205, 98.6 59, 98.3 88, 100.0 58, 96.7 0.258
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clinical failures were detected only in southern and west-
ern Myanmar. Molecular markers analysis augments 
additional information on the pattern of drug resistance. 
In this study, molecular maker analysis indicated wide-
spread distribution of chloroquine, antifolate and multi-
drug resistance markers, with the highest mutant rate in 
southern Myanmar.
Surveillance on drug resistance malaria is of great con-
cern for global control and elimination of malaria. As 
drug-resistant vivax was reported as early as 1980s, its 
exact global burden is still unknown. Compared to fal-
ciparum malaria, drug resistance studies of vivax which 
focus on epidemiology, drug efficacy and drug resist-
ance mechanism are rare. Drug resistance malaria can 
be detected by in  vivo TES studies, molecular maker 
analysis, in vitro drug susceptibility testing and drug con-
centration measurement.
Lack of a standardized culture system limits the useful-
ness of in vitro susceptibility tests for detection of drug 
resistance. Although in  vivo TES were accepted as a 
standard method for drug resistance detection, recurrent 
parasitaemia cases needed to be distinguished between 
re-infection, recrudescence or relapse. Relapse patterns 
of vivax malaria also widely differ across geographical 
regions and no standardized method to exclude relapse 
or re-infection in TF cases leads to difficulties in inter-
pretation of findings of TES. Currently, clinical surveil-
lance with chloroquine drug level measurement has 
been accepted to confirm chloroquine-resistant vivax 

































































































Fig. 2 Molecular marker analysis of drug resistance in vivax malaria in three sentinel sites in Myanmar (2014–2016). A total of 208 from three sen‑
tinel sites were included for molecular marker analysis. K10 (AAG) insert of pvcrt‑O gene, and mutations of pvmdr1, pvdhps and pvdhfr were shown. 
Among three sites, the prevalence of all markers except F1076L of pvmdr1 were fewest in Buthidaung site
Page 6 of 8Nyunt et al. Malar J  (2017) 16:117 
Table 3 Prevalence of the individual single nucleotide polymorphisms (SNPs) in all study sites
Prevalence of SNPs were shown as ‘number (percent)’ of respective site. All P value were calculated by Chi square test with 95% CI
NR not relevant to be calculated
Target genes Kawthaung (n = 60) Shwegyin (n = 88) Buthidaung (n = 60) All site (n = 208) P value
pvcrt‑O
 ‘AAG’ insert 40 (66.7) 64 (72.7) 29 (48.3) 133 (63.9) 0.009
pvmdr1
 T958M 60 (100.0) 88 (100.0) 60 (100.0) 208 (100.0) NR
 Y976F 16 (26.7) 15 (17.0) 1 (1.7) 32 (15.4) 0.001
 F1076L 25 (41.7) 43 (48.9) 38 (63.3) 106 (51.0) 0.067
pvdhps
 S382A 32 (53.3) 24 (27.3) 5 (8.3) 61 (29.3) 0.000
 A383G 60 (100.0) 87 (98.9) 30 (50.0) 177 (85.1) 0.000
 K512M 22 (36.7) 10 (11.4) 7 (11.7) 39 (18.8) 0.000
 A553G 55 (91.7) 71 (80.7) 28 (46.7) 154 (74.0) 0.000
pvdhfr
 F57L/I 46 (76.7) 73 (83.0) 35 (58.3) 154 (74.0) 0.001
 S58R 59 (98.3) 88 (100.0) 48 (80.0) 195 (93.8) 0.000
 T61M 45 (75.0) 71 (80.7) 32 (53.3) 148 (71.2) 0.001
 S117T/N 58 (96.7) 86 (97.7) 52 (86.6) 196 (94.2) 0.003
Table 4 Co-prevalence of single nucleotide polymorphisms (SNPs) in different molecular markers in sentinel sites
a  Numbers in parentheses indicate the amino acid position. Mutant amino acids are shown in bold. All sequences were aligned with Sal-1 (P. vivax) reference 
sequences from Plasmodium data base
Target Descriptiona No. isolate/total (%)
Kawthaung (n = 60) Shwegyin (n = 88) Buthidaung (n = 60) All sites (n = 208)
pvcrt‑O Wild type 20 (33.3) 24 (27.3) 31 (51.7) 75 (36.1)
Mutant (AAG insert) 40 (66.7) 64 (72.7) 29 (48.3) 133 (63.9)
pvmdr1 Wild type (T, Y, F) (958, 976, 1976) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Single mutant (M, Y, F) 35 (58.3) 46 (52.3) 22 (36.7) 103 (49.5)
Double mutant (M, Y, L/I) 9 (15.0) 27 (30.7) 37 (61.7) 73 (35.1)
Triple mutant (M, F, L) 16 (26.7) 15 (17.0) 1 (1.7) 32 (15.4)
pvdhps Wild (S, A, K, A) (382, 383, 512, 553) 0 (0.0) 1 (1.1) 30 (50.0) 31 (14.9)
Single mutant (S, G, K, A) 5 (8.3) 15 (17.0) 2 (3.3) 22 (10.6)
Double mutant (S, G, K, G) 18 (30.0) 45 (51.1) 18 (30.0) 81 (38.9)
Double mutant (A, G, K, A) 0 (0.0) 1 (1.1) 0 (0.0) 1 (0.5)
Triple mutant (A, G, K, G) 15 (25.0) 16 (18.2) 3 (5.0) 34 (16.3)
Triple mutant (S, G, E, G) 0 (0.0) 2 (2.3) 0 (0.0) 2 (1.0)
Triple mutant (S, G, M, G) 5 (8.3) 1 (1.1) 5 (8.3) 11 (5.3)
Quadruple mutant (A, G, M, G) 17 (28.3) 6 (6.8) 2 (3.3) 25 (12.0)
Quadruple mutant (C, G, E, G) 0 (0.0) 1 (1.1) 0 (0.0) 1 (0.5)
pvdhfr Wild (F, S, T, S) (57, 58, 61, 117) 0 (0.0) 0 (0.0) 5 (8.3) 5 (2.4)
Single mutant (L, S, T, S) 1 (1.7) 0 (0.0) 2 (3.3) 3 (1.4)
Single mutant (F, R, T, S) 1 (1.7) 0 (0.0) 0 (0.0) 1 (0.5)
Single mutant (F, S, T, T/N) 0 (0.0) 0 (0.0) 5 (8.3) 5 (2.4)
Double mutant (L, R, T, S) 0 (0.0) 2 (2.3) 1 (1.7) 3 (1.4)
Double mutant (F, R, T, N) 13 (21.7) 14 (15.9) 15 (25.0) 42 (20.2)
Triple mutant (L, R, T, T) 0 (0.0) 1 (1.1) 0 (0.0) 1 (0.5)
Triple mutant (F, R, M, T) 0 (0.0) 1 (1.1) 0 (0.0) 1 (0.5)
Quadruple mutant (L/I, R, M, T/N) 45 (75.0) 70 (79.5) 32 (53.3) 147 (70.7)
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concentration of chloroquine plus desethylchloroquine 
more than 100  ng/mL was observed in ten countries: 
Brazil, Ethiopia, Indonesia, Malaysia (Borneo), Myanmar, 
Papua New Guinea, Peru, the Solomon Islands, and Thai-
land [6].
Although there are no validated molecular markers 
for drug-resistant vivax malaria, potential candidates 
were reported. Most of these candidate markers [7–9] 
were homologues of falciparum drug resistance makers, 
such as pvmdr1, pvdhp and pvdhfr. K10 insertion (‘AAG’ 
insert) in first exon at tenth position of pvcrt-O was also 
suggested as a chloroquine resistance marker [7, 10]; it 
was observed in Thailand (56–89%) [7, 10] and Myan-
mar (46%) [7]. In this study, the highest rate of K10 inset 
alleles was observed in Shwegyin (central Myanmar) 
(72.7%) followed by Kawthaung (southern Myanmar) 
(66.7%) and Buthidaung (western Myanmar) (48.3%) 
indicating high chloroquine resistance in southern 
Myanmar, which is similar to the artemisinin resistance 
status [11]. As the chloroquine is the first line treatment 
for vivax malaria in Myanmar, K10 insert of pvcrt-O gene 
was widely distributed in all three study sites.
Y976F mutation of pvmdr1 was found to be associated 
with reduced susceptibility of chloroquine in Thailand 
and Indonesia [12] but not in Madagascar [13]. Moreo-
ver, Y976F of pvmdr1 gene has been associated with 
higher susceptibility to artesunate and mefloquine [12]. 
In this study, Y976F was detected in Kawthaung (26.7%), 
Shwegyin (17.0%) and Buthidaung (1.7%). Compared 
to neighbouring countries, Y976F was highest in Cam-
bodia (89%) [14], followed by Thailand (8–25%) [10, 14, 
15], China–Myanmar border (3%) [16], and India (0%) 
[17]. Another mutation of pvmdr1, F1096L was observed 
widely but was suggested to be neutral for drug resistance 
[18]. In combined analysis of pvcrt-O and pvmdr1 muta-
tions, chloroquine resistance markers were widely dis-
tributed in all three study sites but with a lower mutant 
rate in western Myanmar.
Similarly, pvdhps and pvdhfr showed a significant role 
in antifolate drug-resistant vivax malaria [19]. F57I/L, 
S58R, T61M, and S117T/N of pvdhfr were found to 
be associated with pyrimethamine resistance [20] and 
S382A, S383G, A553G of pvdhps were associated with 
sulfadoxine resistance [21]. Plasmodium vivax was sup-
posed to have a certain degree of innate resistance to 
sulfadoxine and S383G and A553G could be responsible 
inducers for resistance [22]. In Myanmar, relatively high 
rates of these mutations were noted in southern and cen-
tral Myanmar.
Double mutations (S58R and S117T/N) or quadruple 
mutations (F57L/I, S58R, T61M, and S117T) of pvd-
hfr gene were found in Thailand (96%), Myanmar (71%), 
Korea (1%), Cambodia (94%), and India (40%) [23, 24]. 
In this study, overall quadruple mutations was 147/208 
(70.7%) and contributed more than half of samples in 
all three study sites, indicating high pyrimethamine 
resistance in Myanmar. According to pvdhps and pvdhfr 
data, antifolate resistance in vivax infection in Myanmar 
should not be neglected, although sulfadoxine-pyrimeth-
amine is not the drug of choice for vivax malaria.
Within 2009–2016, treatment regimen for vivax 
malaria was not changed and trend on clinical efficacy of 
chloroquine is similar except some fluctuations in Kaw-
thaung study site. It is difficult to rule-out the drug resist-
ance factor resulting in treatment failure in this study 
sites without molecular analysis in previous years. As 
the drug resistance alone is not responsible for treatment 
failure [4], clinical response and prevalence of molecular 
markers is not similar in this study.
Conclusions
This study is the first multisite, clinical and molecular 
surveillance of drug-resistant vivax malaria in Myanmar, 
exploring the neglected niche of the infection. According 
to current anti-malarial treatment guidelines in Myan-
mar, chloroquine is the first-line treatment for vivax 
malaria. Most of the study sites showed 100% ACPR 
except in the southern and western Myanmar sites. Wide 
distribution of chloroquine and antifolate resistance 
molecular markers revealed the spread of the drug-resist-
ant parasite population in Myanmar. High mutant rates 
of most of the vivax drug resistance molecular markers 
in southern and central Myanmar were similar to that 
of artemisinin resistance falciparum malaria, indicating 
higher anti-malarial resistance burden of falciparum and 
vivax in southern Myanmar. An appropriate strategy and 
action plan to contain or eliminate drug-resistant vivax 
malaria in Myanmar is recommended.
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